Equity Research, Broker Reports, and media content on SANTHERA PHARMACEUTICALS-REG

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about SANTHERA PHARMACEUTICALS-REG
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on SANTHERA PHARMACEUTICALS-REG. We currently have 0 research reports from 0 professional analysts.

Date Source Announcement
23Dec16 06:00 GNW Santhera's Raxone® designated Promising Innovative Medicine and suitable candidate for further evaluation under UK Early Access to Medicines Scheme (EAMS) for treatment in Duchenne muscular dystrophy
08Nov16 06:00 GNW Swissmedic Accepts for Review Santhera's Marketing Authorization Application for Raxone® for the Treatment of Duchenne Muscular Dystrophy
04Oct16 06:01 GNW Santhera announces appointment of Kristina Timdahl as Chief Medical Officer and Head of Development as of January 2017
28Sep16 06:00 GNW Santhera Starts Phase III Study (SIDEROS) with Raxone in Patients with Duchenne Muscular Dystrophy Using Glucocorticoids
13Sep16 06:00 GNW Leading medical journal publishes treatment effect of Santhera's Raxone on inspiratory function in patients with Duchenne muscular dystrophy (DMD)
08Sep16 06:00 GNW Santhera's Idebenone (Raxone) Receives Orphan Drug Designation for Duchenne Muscular Dystrophy in Australia
06Sep16 06:00 GNW Santhera Announces Financial Results for the First Half Year 2016 and Reports Solid Sales Growth - Company Starts to Build US Operations and Strengthens Board of Directors
  • Frequency of research reports


  • Research reports on


  • Providers covering